NMC.L Regulatory News (NMC)

NMC Health PLC (UK): Suspension of Listing

Treatment in FTSE Russell Indexes - Final Update

Further to the notice published 13 March 2020, FTSE Russell would like to confirm the following treatment in regards to the NMC Health trading suspension, and specifically the price which will be assigned to NMC Health.

FTSE Russell has concluded to replace the NMC Health close price on Wednesday 18 March 2020 with the Depository Receipt OTC close price (SEDOL BWWC450) from Thursday 12 March 2020 - the latest close price prior to the publication of the FTSE Russell notice on 13 March 2020. This is intended to ensure that index treatment does not create any unintended consequences to the trading activity and pricing of the NMC Health DR OTC line.

Therefore the price which will be assigned to NMC Health at the close on Wednesday 18 March 2020, and ongoing, will be 111.63p (ADR close price X spot (exchange) rate on Thursday 12 March 2020).

For the avoidance of doubt, if and once NMC Health resumes trading on the London Stock Exchange (LSE), the index price will revert back to the LSE price and the treatment detailed within the 04 March 2020 notice will be followed.

If NMC Health does not resume trading and it has been concluded to remove NMC Health in accordance with the Suspended Stocks' rule, FTSE Russell will further consult (via an Informative Notice) on the price which the deletion will be processed (e.g. zero or OTC DR price).

FTSE Russell will continue to monitor and provide updates in 20 business day increments in accordance with the Suspended Stocks' rules.

FTSE Russell intends to review the Suspended Stocks' rule within the Corporate Action guide with a view to clarifying the price which a suspended stock may be held, while there is another security trading that provides an appropriate valuation proxy.

If you have any questions, please contact your Client Service team.